Matthew S. Capehorn
Rotherham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Journal: Lancet (London, England)
Published: March 09, 2026
The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.
Journal: Journal of medical economics
Published: October 15, 2025
Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.
Journal: Advances in therapy
Published: March 05, 2025
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
Journal: Diabetes, obesity & metabolism
Published: July 12, 2023
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
Journal: Cardiovascular diabetology
Published: April 26, 2022
The Potential Role of Digital Health in Obesity Care.
Journal: Advances in therapy
Published: April 14, 2022
Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee.
Journal: Advances in therapy
Published: November 03, 2021
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 12, 2020
Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model.
Journal: Clinical obesity
Published: September 07, 2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 29, 2020
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Journal: Advances in therapy
Published: February 20, 2020
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 31, 2020
Last Updated: 09/26/2026